Navigation Links
BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
Date:11/12/2007

of attack in many MS patients. This is accomplished by the I.V. injection of MBP8298 every six months.

Phase II and long-term follow-up treatment of MS patients with MBP8298, recently published in the European Journal of Neurology showed that MBP8298 safely delayed the median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.

MBP8298 is being developed in three late-stage clinical trials:

- MAESTRO-01: A pivotal phase III trial in Canada and Western Europe

evaluating MBP8298 for the treatment of secondary progressive

multiple sclerosis (SPMS). The trial is a randomized, double-blind

study and is fully recruited with 611 patients.

- MAESTRO-03: A pivotal phase III U.S. trial evaluating MBP8298 for the

treatment of SPMS. The trial is a randomized, double-blind study

enrolling approximately 510 patients.

- MINDSET-01: A phase II trial evaluating MBP8298 for the treatment of

relapsing remitting multiple sclerosis (RRMS). The trial is a

randomized, double-blind study and is fully recruited with 218

patients.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Com
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Globus Medical Announces Record 2nd Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Rhythm announced today ... of RM-131, the company,s novel ghrelin agonist for the ... The trial demonstrated that RM-131 significantly accelerates early gastric ... 1 diabetic patients with diabetic gastroparesis. The findings were ... Orlando and recently published in ...
(Date:5/20/2013)... On 25-28 July, 2013, UPCP 2013 will convene ... beautiful city of lights. , According to Prof. Eddy ... medical world. Understanding and integrating genetic and molecular information ... transformation. Much of the present medical practice is based ... large cohorts that do not take into account the ...
(Date:5/19/2013)... May 19, 2013 Switzerland’s MS ... announced a new speed record for a transatlantic crossing ... Palmas, Spain, on April 25, 2013, the solar powered ... at the average speed of 5.3 knots before reaching ... May 18, 2013. The first-of-its-kind catamaran completed this year’s ...
(Date:5/17/2013)... 17, 2013 Oven Industries Inc. announces ... 5R6-900 temperature controller has many user-friendly benefits. Contained all ... the wall as a self-contained temperature control ... detail makes the device unique, as well as highly ... also be used universally, which allows the user to ...
Breaking Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6New Temperature Control Products Announced by Oven Industries Inc. 2
... device inventor to drive innovation and product ... development ... Inc.,(OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, ... its Chief,Technical Officer and Vice-President of Research and Development, effective,October ...
... Glycotex, Inc. today announced,enrollment of the first patient ... GLYC-101 on wound closure and cosmetic outcomes in ... on the lower,eyelid area., A previous Phase ... of GLYC-101 at two doses compared to placebo ...
... Emerging Chinese Companies, HAIKOU CITY, Hainan, China, ... Pharma") (OTC Bulletin Board: CPHI),which develops, manufactures, and ... announced the appointment of,The Ruth Group (TRG) as ... President and CEO of China Pharma Holdings, Inc.,commented, ...
Cached Biology Technology:Dorin Panescu Named NewCardio's Chief Technical Officer 2Dorin Panescu Named NewCardio's Chief Technical Officer 3Dorin Panescu Named NewCardio's Chief Technical Officer 4Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing 2Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing 3China Pharma Holdings, Inc. Appoints The Ruth Group 2China Pharma Holdings, Inc. Appoints The Ruth Group 3
(Date:5/17/2013)... Ill. An international team of ... structure and cell movement inside a living frog embryo ... a new method to advance biological research and the ... Northwestern University and the Karlsruher Institut fr Technologie in ... the U.S. Department of Energy,s Argonne National Laboratory, released ...
(Date:5/16/2013)... to Research Careers) Program has announced the travel ... (SDB) 72nd Annual Meeting in Cancun, Mexico from ... promote the entry of students, postdoctorates and scientists ... basic science community and to encourage the participation ... Meeting. , Awards are given to poster/platform presenters ...
(Date:5/16/2013)... gene involved in neurodegenerative disease also plays a critical ... , In a study of the common fruit ... the clock responsible for sleeping and waking on a ... fruit fly,s sleep-wake cycle is disturbed, making waking up ... , The discovery is particularly interesting because mutations in ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Gene involved in neurodegeneration keeps clock running 2
... researching the behavior of field crickets have found for ... based on the latter,s song, and use this information ... crickets compare the information about the attractiveness of available ... attractive males for mating. The finding shows that ...
... the presence of the rare element osmium is on ... consumption of refined platinum, the primary ingredient in catalytic ... smog. A volatile form of osmium is generated during ... cars, and it gets dispersed globally through the atmosphere. ...
... chronic infections in cystic fibrosis patients use one of ... a structure that helps the microbes resist efforts to ... that the bacterial cell-surface sugar, a polysaccharide called Psl, ... a helix, providing a structure that encourages cell-to-cell interaction. ...
Cached Biology News:Remembrance of things past influences how female field crickets select mates 2Remembrance of things past influences how female field crickets select mates 3Increasing levels of rare element found worldwide 2Sugar on bacteria surface serves as base for a web of resistance 2Sugar on bacteria surface serves as base for a web of resistance 3
Human SOST Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Human Legumain Affinity Purified Polyclonal Ab...
Biology Products: